Summary
Becton, Dickinson and Company (BDX) announced a significant leadership transition within its Life Sciences Segment. Patrick K. Kaltenbach, the Executive Vice President and President of the Life Sciences Segment, is departing the company effective January 21, 2021, to take an executive role in Europe. This move is motivated by a desire to be closer to his family. As a consequence of Mr. Kaltenbach's departure, Dave Hickey, currently President of BD’s Integrated Diagnostics Solutions business unit, will assume the role of President, Life Sciences Segment, starting January 1, 2021. The company also revealed that its planned succession for the Chief Technology Officer role will be adjusted. John DeFord, the current EVP and Chief Technology Officer, who was set to retire, will postpone his retirement until at least May 28, 2021, to continue overseeing the company's innovation strategy and R&D pipeline.
Key Highlights
- 1Patrick K. Kaltenbach, EVP and President, Life Sciences Segment, is leaving BDX effective January 21, 2021.
- 2Mr. Kaltenbach's departure is for an executive leadership position in Europe to be closer to his family.
- 3Dave Hickey will succeed Mr. Kaltenbach as President, Life Sciences Segment, effective January 1, 2021.
- 4Mr. Hickey currently serves as President of BD’s Integrated Diagnostics Solutions business unit.
- 5John DeFord, EVP and Chief Technology Officer, will postpone his previously announced retirement.
- 6Mr. DeFord will continue to lead innovation strategy and R&D pipeline until at least May 28, 2021.